Abstract
To assess the relevance of MYCN amplification and bone lesions in stage 4 neuroblastoma (NB) in infants aged <1 year, 51 infants with stage 4 NB were enrolled. Three groups of patients were defined according to the type of metastases and the resectability of the primary tumour. Group I comprised 21 infants with radiologically detectable bone lesions, Group II 22 patients with an unresectable primary tumour and Group III eight patients with only metaiodobenzylguanidine (MIBG) skeletal uptake. MYCN oncogene content was assayed in 47/51 tumours and found to be amplified in 17 (37%). The 5-year event-free survival (EFS) rate of these 51 infants was 64.1% (± 7.1%). In a univariate analysis, bone lesions, MYCN amplification, urinary vanillylmandelic/homovanillic acid ratio and serum ferritin levels adversely influenced outcome. In the multivariate analysis, radiologically detectable bone lesions were the most powerful unfavourable prognostic indicator: the EFS rate was 27.2% for these infants compared to 90% for infants without bone lesions (P < 0.0001). Our data emphasize the poor prognosis of infants affected by stage 4 NB with bone lesions, especially when associated with MYCN amplification. Given the poor results in this group whatever the treatment, new therapeutic approaches need to be investigated in the future. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robinson L, Shuster J, Byrne T, Gregory D, Hill G, Dougherty G, Scriver C, Lemieux B, Tuchman M and Woods WG (1992) A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 10: 323–329
Bertani-Dziedzic L, Dziedzic SW and Gitlow SE (1990) Catecholamine metabolism in neuroblastoma. in Pochelldly C (ed): Neuroblastoma: Tumor Biology and therapy, Boca Raton, FL,CRC; (ed): 69–91
Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA and Look AT (1997) Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group Study. J Natl Cancer Inst 89: 373–380
Brodeur GM, Pritchard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee REJ, Look T, Pearson ADJ, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y and Voute PA (1993) Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and response to Treatment. J Clin Oncol 11: 1466–1477
Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavarda N, Schneider S, Wasson J, White P, Seeger R, Look T and Castleberry RP (1992) Neuroblastoma: Effects of genetics on prognosis and treatment. Cancer 70: 1685–1694
Caron H (1993) In neuroblastoma alletic loss chromosome 1 p and the presence of additional chromosome 17 q material are both associated with an unfavorable outcome. Twenty-fifth Annual Meeting of the International Society of Pediatric Oncology, San Francisco, CA, October 5–9,
Castel Sanchez V, Melero Moreno C, Garcia-Miguel Garcia-Rosados A, Navajas Gutierrez A, Ruiz Jimenez JI, Navarro Fos S, Garin Valle JC and Galbe Sada M (1997) Neuroblastoma en ninos menores de 1 ano. An Esp Pediatr 47: 584–590
Cox DR (1977). The analysis of Binary Data, London, England,Chapman & Hall
Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, Plouvier E, Leverger G, Bordigoni P, Behar C, Beck D, Mechinaud F, Bergeron C, Plantaz D, Otten J, Zucker JM, Philip T and Bernard JL (1997) NB 87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 15: 3433–3440
De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT, Cordero Di Montezemolo L, Lanino E, Clerico A, Rogers DW and Bruzzi P (1992) Disseminated Neuroblastoma (Stage IV and IV-S) in the first year of life. Cancer 70: 1625–1633
Carlsen NL, Schroeder H, Bro PV, Erichsen G, Hamborg-Pedersen B, Jensen KB and Nielsen OH (1985) Neuroblatomas treated at the four major child oncologic clinics in Denmark 1943–1980: an evaluation of 180 cases. Med Pediatr Oncol 13: 180–186
Dubois G, Kalika Y, Lukens J, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO and Matthay KK (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol-Oncol 21, (3)181–189
Evans AE, D’Angio GJ and Randolph J (1971) A proposed staging for children with neuroblastoma. Cancer 27: 374–378
Fleiss JI (1981). Statistical Methods for Rates and Proportions (ed 2), New York, NY, Wiley
Frappaz D, Michon J, Hartmann O, Bouffet E, Lejars O, Gentet JC, Chastagner P, Sariban E, Brugiere L, Zucker JM, Lemerle J and Philip T (1992) Etoposide and carboplatin in neuroblastoma: A French Society of Pediatric Oncology phase II study. J Clin Oncol 10: 1592–1601
Goon HK, Cohen DH and Harvey JG (1984) Review of thoracic neuroblastoma. Aust Paediatr J 20: 17–21
Hahn HWL, Levy HM and Evans AE (1980) Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 40: 1411–1413
Labreveux de Cervens C, Hartmann O, Bonnin F, Couanet D, Valteau-Couanet D, Lumbroso J, Behar C, Martelli H and Lemerle J (1994) What is the prognostic value of osteomedullary uptake on MIBG Scan in neuroblastoma patients under one year of age?. Med Pediatr Oncol 22: 107–114
Lampert F, Chritiansen H, Terpe HJ and Berthold F (1997) Disseminated neuroblastomas under 1 year of age: cell biology and prognosis. Jour of neuro-Onc 31: 181–184
Look AT, Hayes FA, Nitschke R, McWilliams NB and Green AA (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311: 231–235
Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI and Brodeur GM (1991) Clinical relevance of tumor cell ploidy and N-Myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9: 581–591
McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH and Ackery DM (1985) Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 25: 132–153
Michon J, Hartmann O, Frappaz D, Chastagner P, Rubie H, Perel Y, Sariban E, Wyss M, Legall E, Courbon B, Philip T, Lemerle J and Zucker JM (1993) Adaptation of the treatment to clinical presentation in stage 4s neuroblastoma. Results of the French Society of Pediatric Oncology NBL 90 prospective study. Med Ped Oncol 21: 585 (Abstract p 122)
Nakagawara A, Ikeda K, Tsuda T and Hisashi K (1987) N-Myc oncogene amplification and prognostic factors of neuroblastoma in children. J Pediatr Surg 22: 895–898
Paul SR, Tarbell NJ, Korf B, Kretschmar CS, Lavally B and Grier H (1991) Stage 4 neuroblastoma in infants. Cancer 67: 1493–7
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG (1977) Design and analysis of clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39
Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bernard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J and Sommelet D (1997) N-Myc Gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 Study. J Clin Oncol 15: 1171–1182
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY and Hammond D (1985) Association of multiples copies of the N- Myc oncogene with rapid progression of neuroblastoma. N Engl J Med 313: 1111–1116
Shuster JH, McWilliams NB, Castelberry R, Nitschke R, Smith EI, Altshuler G, Kun L, Brodeur G, Joshi V, Vietti T and Hayes FA (1992) Serum lactate deshydrogenase in childhood neuroblastoma. Am J Clin Oncol 15: 295–303
Strother D, Shuster JJ, McWilliams N, Nitschke R, Smith EI, Joshi V, Kun L, Hayes FA and Castleberry R (1995) Results of pediatric Oncology Group Protocol 8104 for infants with stage D and DS Neuroblastoma. Journ of Pediatr Hem-Oncol 17, (3)254–259
Zeltza PM, Marangos PJ, Evans AE and Schneider SL (1986) Serum neuron specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 57: 1230–1234
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Minard, V., Hartmann, O., Peyroulet, M. et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology. Br J Cancer 83, 973–979 (2000). https://doi.org/10.1054/bjoc.2000.1412
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1412
Keywords
This article is cited by
-
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol
BMC Pediatrics (2020)
-
Neuroblastoma
Clinical and Translational Oncology (2005)